Back To Search Results

CHA2DS2-VASc Score for Atrial Fibrillation

Editor: Scott C. Dulebohn Updated: 11/5/2023 7:09:32 AM

Summary / Explanation

Atrial fibrillation (AF), a common heart rhythm disorder, significantly increases the risk of stroke. To help clinicians evaluate this risk, the CHA2DS2-VASc score has emerged as a valuable tool. This scoring system aids healthcare professionals in assessing the likelihood of stroke in patients with non-valvular AF, thus guiding treatment decisions and enhancing patient care. Atrial fibrillation is characterized by an irregular and often rapid heart rhythm. In this condition, blood can pool in the atria, forming clots that may travel to the brain and cause a stroke.[1]

The CHA2DS2-VASc score, introduced as an improvement over the CHADS2 score, was developed to offer a more comprehensive evaluation of stroke risk in patients with AF. The CHA2DS2-VASc score serves a crucial purpose in clinical practice. It assists healthcare providers in stratifying patients with AF into different risk categories for stroke. The score helps guide decisions regarding anticoagulation therapy, balancing the necessity for stroke prevention with the potential risks of bleeding associated with these medications.[2]


The acronym CHA2DS2-VASc stands for:

  • Congestive heart failure (1 point): This component accounts for the presence of heart failure, which can contribute to stroke risk.
  • Hypertension (1 point): High blood pressure is a well-established risk factor for stroke.
  • Age (≥75 years, 2 points): Age significantly impacts stroke risk. The older a patient is, the higher their score.
  • Diabetes (1 point): Diabetes is a significant risk factor for stroke, especially in combination with AF.
  • Stroke or TIA (2 points): A history of stroke or transient ischemic attack (TIA) indicates a high risk of future stroke.
  • Vascular disease (1 point): This component covers a history of myocardial infarction, peripheral artery disease, or aortic plaque.
  • Age (between 65 and 74 years, 1 point): Patients aged 65 to 74 receive one point in this category.
  • Sex category (female, 1 point): Women are assigned one point, as they may be at higher risk for stroke.


The CHA2DS2-VASc score has become a standard tool in clinical practice. Healthcare providers calculate the score for each AF patient, adding up the points from the components described above. The total score determines the patient's risk category:[3]

  • 0: Low risk (no anticoagulation is required.)
  • 1: Moderate risk (consider anticoagulation based on individual factors.)
  • 2 or more: High risk (anticoagulation therapy is recommended.)

The CHA2DS2-VASc score is especially useful for identifying patients with a low risk of stroke (ie, males with a score of 0 and females with a score of 1). This system allows for a more personalized approach to stroke prevention in AF, balancing the potential benefits and risks of anticoagulant therapy.


While the CHA2DS2-VASc score is a valuable tool, it does have limitations:

  1. It does not account for the quality of anticoagulation control, which is important in assessing the effectiveness of treatment.

  2. It may not be equally applicable to all populations, as some factors included in the score's components may have varying degrees of influence in different patient groups.

  3. The score does not provide information about individual bleeding risk, which is essential in determining the net benefit of anticoagulation therapy.

  4. The scale was developed when vitamin K antagonists (warfarin) were the predominant anticoagulation method, and there is a shift towards using direct oral anticoagulants, which may have a safer use profile.[4]

The CHA2DS2-VASc score plays a critical role in evaluating stroke risk in patients with atrial fibrillation. When used alongside clinical judgment, it helps healthcare providers make informed decisions regarding anticoagulation therapy, ultimately improving patient care and reducing the risk of stroke in this at-risk population. However, clinicians should be mindful of the score's limitations and consider them in their decision-making process.

Other Uses

Although these criteria are meant to apply specifically to patients with atrial fibrillation to create a risk-benefit profile for stroke risk, this scale has also been studied in patients to estimate other adverse events like cardiovascular outcomes and mortality. Some patient groups in whom this has been studied also include patients without atrial fibrillation but who have congestive heart failure, coronary artery disease, or other conditions. Further studies are needed to validate this scale for non-stroke outcomes and non–atrial fibrillation populations.[5][6][7]

Register For Free And Read The Full Article
Get the answers you need instantly with the StatPearls Clinical Decision Support tool. StatPearls spent the last decade developing the largest and most updated Point-of Care resource ever developed. Earn CME/CE by searching and reading articles.
  • Dropdown arrow Search engine and full access to all medical articles
  • Dropdown arrow 10 free questions in your specialty
  • Dropdown arrow Free CME/CE Activities
  • Dropdown arrow Free daily question in your email
  • Dropdown arrow Save favorite articles to your dashboard
  • Dropdown arrow Emails offering discounts

Learn more about a Subscription to StatPearls Point-of-Care



Gutierrez C, Blanchard DG. Diagnosis and Treatment of Atrial Fibrillation. American family physician. 2016 Sep 15:94(6):442-52     [PubMed PMID: 27637120]


Joundi RA, Cipriano LE, Sposato LA, Saposnik G, Stroke Outcomes Research Working Group. Ischemic Stroke Risk in Patients With Atrial Fibrillation and CHA2DS2-VASc Score of 1: Systematic Review and Meta-Analysis. Stroke. 2016 May:47(5):1364-7. doi: 10.1161/STROKEAHA.115.012609. Epub 2016 Mar 29     [PubMed PMID: 27026630]

Level 1 (high-level) evidence


van Doorn S, Debray TPA, Kaasenbrood F, Hoes AW, Rutten FH, Moons KGM, Geersing GJ. Predictive performance of the CHA2DS2-VASc rule in atrial fibrillation: a systematic review and meta-analysis. Journal of thrombosis and haemostasis : JTH. 2017 Jun:15(6):1065-1077. doi: 10.1111/jth.13690. Epub 2017 May 9     [PubMed PMID: 28375552]

Level 1 (high-level) evidence


Jagadish PS, Kabra R. Stroke Risk in Atrial Fibrillation: Beyond the CHA(2)DS(2)-VASc Score. Current cardiology reports. 2019 Jul 27:21(9):95. doi: 10.1007/s11886-019-1189-6. Epub 2019 Jul 27     [PubMed PMID: 31352536]


Melgaard L, Gorst-Rasmussen A, Lane DA, Rasmussen LH, Larsen TB, Lip GY. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation. JAMA. 2015 Sep 8:314(10):1030-8. doi: 10.1001/jama.2015.10725. Epub     [PubMed PMID: 26318604]


Teodorovich N, Gandelman G, Jonas M, Fabrikant Y, Swissa MS, Shimoni S, George J, Swissa M. The CHA(2)DS(2)-VAS(C) Score Predicts Mortality in Patients Undergoing Coronary Angiography. Life (Basel, Switzerland). 2023 Oct 9:13(10):. doi: 10.3390/life13102026. Epub 2023 Oct 9     [PubMed PMID: 37895408]


Steensig K, Olesen KKW, Thim T, Nielsen JC, Madsen M, Jensen SE, Jensen LO, Kristensen SD, Lip GYH, Maeng M. Predicting stroke in patients without atrial fibrillation. European journal of clinical investigation. 2019 Jun:49(6):e13103. doi: 10.1111/eci.13103. Epub 2019 Apr 3     [PubMed PMID: 30883728]